These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21270668)

  • 61. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.
    Harrison LH; Schwarzenberger PO; Byrne PS; Marrogi AJ; Kolls JK; McCarthy KE
    Ann Thorac Surg; 2000 Aug; 70(2):407-11. PubMed ID: 10969653
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Localized benign fibrous mesothelioma mimicking a malignant tumor of the pleura.
    Desrumaux I; Baekelandt M; Verbeke W; Gryspeerdt S; Van Holsbeeck B; Lefere P
    JBR-BTR; 1998 Jun; 81(3):131-3. PubMed ID: 10547262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
    Colin DJ; Bejuy O; Germain S; Triponez F; Serre-Beinier V
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904012
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An unusual presentation of malignant pleural mesothelioma.
    Lacle MM; van Oosterhout MF
    J Thorac Oncol; 2013 Jul; 8(7):e63-4. PubMed ID: 23774388
    [No Abstract]   [Full Text] [Related]  

  • 65. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
    Truong MT; Marom EM; Erasmus JJ
    J Thorac Imaging; 2006 May; 21(2):146-53. PubMed ID: 16770231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
    Nowak AK; Armato SG; Ceresoli GL; Yildirim H; Francis RJ
    Lung Cancer; 2010 Oct; 70(1):1-6. PubMed ID: 20541834
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
    Armato SG; Blyth KG; Keating JJ; Katz S; Tsim S; Coolen J; Gudmundsson E; Opitz I; Nowak AK
    Lung Cancer; 2016 Nov; 101():48-58. PubMed ID: 27794408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PET-CT in the diagnosis of localized malignant pleural mesothelioma.
    Dimarakis I; Rehman S; Machaal A; Shah R
    Clin Imaging; 2011; 35(6):476-7. PubMed ID: 22040794
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
    Warby A; Dhillon HM; Kao S; Vardy JL
    Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Usefulness of new flex-rigid pleuroscopy in the diagnosis of malignant pleural mesothelioma.
    Ishii S; Ishii Y; Kaburagi T; Nakano T
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30642855
    [No Abstract]   [Full Text] [Related]  

  • 72. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
    Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
    Otsuka H; Terazawa K; Morita N; Otomi Y; Yamashita K; Nishitani H
    J Med Invest; 2009 Feb; 56(1-2):16-20. PubMed ID: 19262009
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Malignant mesothelioma in an adolescent boy.
    Varan A; Kara A; Haliloğlu M; Büyükpamukçu M; Ayhan A; Ruacan S
    Pediatr Int; 1999 Dec; 41(6):693-5. PubMed ID: 10618893
    [No Abstract]   [Full Text] [Related]  

  • 76. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
    Buikhuisen WA; Qayyum F; Armato SG; Baas P
    Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
    [No Abstract]   [Full Text] [Related]  

  • 77. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Computerized analysis of mesothelioma on CT scans.
    Armato SG
    Lung Cancer; 2005 Jul; 49 Suppl 1():S41-4. PubMed ID: 15950800
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
    Kato K; Gemba K; Fujimoto N; Aoe K; Takeshima Y; Inai K; Kishimoto T
    Anticancer Res; 2016 Mar; 36(3):1067-72. PubMed ID: 26976999
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimal Therapy of Advanced Stage Mesothelioma.
    Disselhorst MMJ; Burgers SJA; Baas P
    Curr Treat Options Oncol; 2017 Aug; 18(8):48. PubMed ID: 28681207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.